Socazolimab combined with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China

• Lian Tang ,

  Contributed equally to this work with: Lian Tang, Yong Chen

  Roles Data curation

  Affiliation Department of pharmacy, Affiliated hospital 2 of Nantong University, and Nantong First People’s Hospital, Nantong, Jiangsu Province, China

  ⨯
• Yong Chen ,

  Contributed equally to this work with: Lian Tang, Yong Chen

  Roles Data curation

  Affiliation Department of pharmacy, Affiliated hospital 2 of Nantong University, and Nantong First People’s Hospital, Nantong, Jiangsu Province, China

  ⨯
• Shaoqing Zhan,

  Roles Data curation

  Affiliation Department of pharmacy, Affiliated hospital 2 of Nantong University, and Nantong First People’s Hospital, Nantong, Jiangsu Province, China

  ⨯
• Longxun Zhu ,

  Roles Data curation

  * E-mail: 929083891@qq.com (PFF); 948017729@qq.com (LZ)

  Affiliations Department of pharmacy, Affiliated hospital 2 of Nantong University, and Nantong First People’s Hospital, Nantong, Jiangsu Province, China, Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology, Nantong, Jiangsu Province, China

  ⨯
• PanFeng Feng

  Roles Conceptualization, Data curation

  * E-mail: 929083891@qq.com (PFF); 948017729@qq.com (LZ)

  Affiliations Department of pharmacy, Affiliated hospital 2 of Nantong University, and Nantong First People’s Hospital, Nantong, Jiangsu Province, China, Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology, Nantong, Jiangsu Province, China, Nantong Clinical Medical College of Kangda College of Nanjing Medical University, Nanjing, Jiangsu, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China

  https://orcid.org/0000-0001-7817-7971

  ⨯